Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats

CNS Neuroscience and Therapeutics

Volumn 21, Issue 5, 2015, Pages 410-416

  Lan, Lin Fang ^a   Zheng, Lu ^a   Yang, Xian ^b   Ji, Xiao Tan ^a   Fan, Yu Hua ^a   Zeng, Jin Sheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b FUJIAN PROVINCIAL HOSPITAL   (China)

Author keywords

Hypertensive white matter lesion; Inflammation; Peroxisome proliferator activated receptor ; Pioglitazone; Small vessel disease

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FAST BLUE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; PIOGLITAZONE; PROTEIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CAPSULA INTERNA; CELL PROLIFERATION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; ENCEPHALITIS; EXTERNAL CAPSULE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; LEUKOARAIOSIS; LONG TERM CARE; MALE; MEMORY DISORDER; MICROGLIA; MORRIS WATER MAZE TEST; NONHUMAN; PROTEIN EXPRESSION; PUTAMEN; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR REMODELING; WHITE MATTER LESION; AGONISTS; ANIMAL; BLOOD PRESSURE; BRAIN; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; IMMUNOMODULATION; MAZE TEST; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; WHITE MATTER;

ANIMALS; BLOOD PRESSURE; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PPAR GAMMA; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; WHITE MATTER;

EID: 84928080180     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12374     Document Type: Article

References (31)

1. O'Sullivan M. Leukoaraiosis. Pract Neurol 2008;8:26-38.
2. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013;12:483-497.
3. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002;13(Suppl 2):7-10.
4. Wakita H, Tomimoto H, Akiguchi I, Kimura J. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol 1994;87:484-492.
5. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010;81:192-197.
6. DeStefano AL, Atwood LD, Massaro JM, et al. Genome-wide scan for white matter hyperintensity: the Framingham Heart Study. Stroke 2006;37:77-81.
7. Huang YH, Zhang WW, Lin L, et al. Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis? Neuropathol Appl Neurobiol 2010;36:237-247.
8. Fredriksson K, Kalimo H, Nordborg C, Olsson Y, Johansson BB. Cyst formation and glial response in the brain lesions of stroke-prone spontaneously hypertensive rats. Acta Neuropathol 1988;76:441-450.
9. Biran V, Joly LM, Heron A, et al. Glial activation in white matter following ischemia in the neonatal P7 rat brain. Exp Neurol 2006;199:103-112.
10. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006;45:19-28.
11. Diep QN, El MM, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-2302.
12. Tureyen K, Kapadia R, Bowen KK, et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007;101:41-56.
13. Nakamura T, Yamamoto E, Kataoka K, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007;38:3016-3022.
14. Swanson CR, Joers V, Bondarenko V, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011;8:91.
15. McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 2007;205:396-406.
16. Zeng J, Zhang Y, Mo J, Su Z, Huang R. Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats. Stroke 1998;29:1708-1713 1713-1714.
17. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.
18. Pratley RE. The PROactive Study: Pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes. Curr Diab Rep 2006;6:45-46.
19. Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010;41:1798-1806.
20. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009;54:782-787.
21. Gasecki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep 2013;15:547-558.
22. Murray AD, Staff RT, McNeil CJ, et al. Brain lesions, hypertension and cognitive ageing in the 1921 and 1936 Aberdeen birth cohorts. Age (Dordr) 2012;34:451-459.
23. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press 2006;15:135-150.
24. Llorens S, Mendizabal Y, Nava E. Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. Eur J Pharmacol 2007;575:105-112.
25. Hernanz R, Martin A, Perez-Giron JV, et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol 2012;166:1303-1319.
26. Bailey EL, Wardlaw JM, Graham D, Dominiczak AF, Sudlow CL, Smith C. Cerebral small vessel endothelial structural changes predate hypertension in stroke-prone spontaneously hypertensive rats: a blinded, controlled immunohistochemical study of 5- to 21-week-old rats. Neuropathol Appl Neurobiol 2011;37:711-726.
27. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-2235.
28. Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007;25:1021-1026.
29. Huang Y, Zhang W, Lin L, et al. Is endothelial dysfunction of cerebral small vessel responsible for white matter lesions after chronic cerebral hypoperfusion in rats? J Neurol Sci 2010;299:72-80.
30. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 2010;41:1266-1270.
31. Wakita H, Tomimoto H, Akiguchi I, Kimura J. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 1995;26:1415-1422.